HB2738 amends Virginia’s health insurance mandate for mental health and substance use disorder coverage. The bill requires group and individual health insurance policies to cover mental health and substance use disorder benefits for children, adolescents, and adults in parity with medical and surgical benefits, and it expressly ties medical-necessity determinations, prior authorization, and utilization review to “generally accepted standards of mental health or substance use disorder care.” Those standards are defined using evidence-based, independent clinical sources such as peer-reviewed literature, professional association guidelines, federal guidance, and FDA-approved drug labeling.
The bill also specifies that coverage must include mobile crisis response services and support and stabilization services in residential crisis stabilization units or crisis receiving centers when those services are covered in other settings, regardless of billing code differences. For certain grandfathered small-group plans, the bill preserves alternative minimum benefit structures for inpatient, partial hospitalization, and outpatient services if the plan does not fully comply with the parity-based coverage requirements. It also requires the Bureau of Insurance to develop reporting on denied claims, complaints, appeals, network adequacy, and carrier comparative analyses, and to publish an annual public report.
In practical terms, the bill expands and clarifies insurer obligations under Virginia law by limiting the use of insurer-specific criteria that are more restrictive than accepted clinical standards. It affects health carriers, policyholders, and providers by strengthening parity enforcement, broadening access to crisis services, and creating more detailed oversight and reporting requirements for the Bureau of Insurance. The bill applies to policies and contracts when issued, renewed, reissued, extended, or otherwise changed, with exceptions for excepted benefits and Medicare-related or similar governmental coverage.
The overall sentiment reflected in the voting history was strongly favorable, with the bill passing both chambers by wide margins after committee consideration and a substitute/amendment process. The House and Senate votes suggest broad bipartisan support for improving mental health and substance use disorder coverage, though the earlier subcommittee and committee votes indicate some initial scrutiny of the bill’s details. No committee transcript was provided, so the record does not show specific floor or committee arguments beyond the vote patterns.
The main points of contention likely centered on how far to extend parity requirements, how to define and enforce “generally accepted standards of care,” and the administrative impact on insurers, especially regarding utilization review, network adequacy reporting, and coverage of crisis services. The grandfathered small-group plan provisions also suggest a compromise to preserve some legacy benefit structures while moving toward broader parity-based coverage.
The bill amends and reenacts § 38.2-3412.1 of the Code of Virginia, expanding and clarifying mandated health insurance coverage for mental health and substance use disorder treatment. It strengthens parity requirements, directs insurers to use generally accepted clinical standards for medical necessity and utilization review, adds coverage for mobile crisis and crisis stabilization services, and requires annual Bureau of Insurance reporting on claims, complaints, appeals, and network adequacy. It affects group and individual health insurance policies, with limited exceptions for excepted benefits and certain governmental coverage, and includes special rules for grandfathered small-group plans.
The bill appears to have enjoyed broad support throughout the legislative process. It advanced from subcommittee and committee with some opposition, then passed the House and Senate by large margins, and the House later agreed to Senate amendments. The vote pattern suggests general agreement on expanding mental health and substance use disorder coverage, with only limited resistance to the bill’s regulatory and insurance-market implications.
The likely areas of contention were the bill’s use of evidence-based clinical standards to constrain insurer utilization review, the scope of mandated coverage for crisis services, and the added reporting and compliance burden on carriers. Insurers may have been concerned about limits on their ability to apply internal medical-necessity criteria or manage network and claims decisions, while supporters likely emphasized parity, access to care, and transparency. The grandfathered small-group plan provisions indicate that preserving some existing benefit structures was also part of the negotiation.